Regina Castaneda, a research fellow in endocrinology at the Mayo Clinic in Jacksonville, Fla, said in a news release.Casteneda noted that previous studies of semaglutide (Ozempic/Wegovy) yielded similar findings.Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications, Castenada said.More women are using hormone therapy to manage menopause symptoms like hot flashes and night sweats, following research that found such therapy didnt increase risk of diseases like breast cancer and heart disease as dramatically as previously thought.Menopause-related hormone changes often result in increased belly fat and decreased muscle mass, as well as changes in metabolism that contribute to weight gain, researchers said in background notes.For the new study, researchers tracked the weight of 120 postmenopausal women prescribed Zepbound
Add fiber slowly, not suddenly
MC5R in exocrine glands and immune cells
Doses ranging from 5 to 10 grams have been most commonly studied in human trials, though these investigations primarily focused on glycemic control rather than GLP-1 secretion as a primary endpoint
Yet, common side effects of the medication include anxiety, panic attacks, insomnia, irritability, hostile or angry feelings, impulsivity, and restlessness
But calibrating expectations to real-world rather than trial-level outcomes prevents disappointment